Over the last decades, a better understanding of tumor biology and resistance mechanisms in HER2-positive breast cancer has favored the development of new, specific, and more potent anti-HER2 drugs, enriching the therapeutic arsenal. The gene discussed is ERBB2; the disease is neoplasm.